psoriatic arthritis

Redefining immunology care: our pledge to patients and the healthcare community

Vandenbruaene Nathalie — Mon, 23 Sep 2024 08:15:38 +0000

Redefining immunology care: our pledge to patients and the healthcare community

Camille Lee, U.S. Immunology

Vandenbruaene … Mon 23/09/2024 - 10:15

Throughout my career and now in my role as head of U.S. Immunology at ��ֳ�, the stories I hear from patients inspire my work each day. At ��ֳ�, we are dedicated to developing solutions for people living with chronic immune-mediated diseases, including psoriatic arthritis (PsA)—which can affect about 30 percent of people living with psoriasis—as well as lesser-known forms of arthritis like non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).

At the heart of our commitment to addressing gaps in care lies innovation. ��ֳ� is proud to be advancing care with a new solution now available for healthcare providers and their patients.

We know severe rheumatic diseases not only affect physical health but can also impact a person’s ability to take part in everyday activities such as participating in hobbies and recreational activities, socializing with loved ones, and completing household chores. People living with rheumatic diseases often struggle to find long-term disease management solutions that work for them.

That’s why our focus in Immunology at ��ֳ� is developing and providing treatments so that people living with rheumatic or dermatologic diseases, particularly those who have struggled with treatment options, can strive to live their best lives, tackling the activities that once felt like a burden.

��ֳ� is also leading the way in setting higher standards for treatments across immunology. In our PsA clinical trials, we used the American College of Rheumatology (ACR)50 endpoint, which signifies a 50% improvement in symptoms and disease, as a measure of success. This endpoint is more rigorous than the more commonly used ACR20, the 20% improvement marker. By setting this higher standard, we prioritize developing medicines that make a significant impact on patient health.

As our pipeline grows, our approach will continue to evolve to meet the needs of the patient communities we aim to serve. I am confident our bold and exciting research programs will help change the future of immunology care within the next decade.

solutions

144 Likes

��ֳ� Joins the Dermatology Community for #IFPAConference2024

Andrea_Puletto — Thu, 27 Jun 2024 08:17:23 +0000

��ֳ� Joins the Dermatology Community for #IFPAConference2024

Rajesh Gupta, Corporate Dermatology

Andrea_Puletto Thu 27/06/2024 - 10:17

The IFPA Conference 2024, also known as the 7th World Psoriasis and Psoriatic Arthritis Conference, is taking place this week in Stockholm, Sweden, June 27–29. Organized by the International Federation of Psoriatic Associations (IFPA), this conference is held every three years, and the 2024 edition marks the seventh occurrence. The theme of this year’s scientific gathering is “Uncovering the broad spectrum of psoriatic disease.”

��ֳ� is committed to improving the lives of people living with psoriasis and psoriatic arthritis and is a proud diamond sponsor of this event. The conference will bring together clinical experts, healthcare professionals, researchers and advocacy organizations to share the latest research and updates on these immuno-dermatological conditions. The forum provides an excellent opportunity to facilitate the sharing of achievements as well as advancements in preventing, diagnosing, and treating psoriasis and psoriatic arthritis. Additionally, it allows for conversations about the interconnected co-morbidities that can impact patients’ lives.

Psoriasis is a chronic immune-mediated inflammatory skin disease that affects over 125 million people worldwide. An estimated 30% of people living with psoriasis also develop psoriatic arthritis, a progressive inflammatory disease that can cause joint swelling, pain, and stiffness, potentially leading to irreversible joint damage if not properly managed. These diseases are multifaceted with significant physical, emotional and psychological burdens on all aspects of daily life. ��ֳ� has a long-standing commitment to developing solutions aimed at improving the lives of people with psoriasis and psoriatic arthritis.

Here are some highlights of ��ֳ�’s presence at the IFPA Conference 2024:

Scientific abstracts: ��ֳ� will present its latest research across seven abstracts with five focused on psoriasis and two focused on psoriatic arthritis.
Scientific symposium: ��ֳ� will host a scientific symposium entitled “Exploring the patients’ path: how can we raise the standard of care in psoriatic disease?’ on Friday 28th June between 12:15 and 13:15 CET. Leading opinion leaders will discuss and debate the latest developments in psoriasis and psoriatic arthritis.
Exhibition booth: Delegates can also visit the ��ֳ� exhibition booth to interact with the on-site ��ֳ� team and learn more about the immuno-dermatology portfolio.

A key contributing factor to future advances in immuno-dermatology is collaboration and partnership with the global community. ��ֳ� is committed to maintaining deep connections with patients and the scientific community, to enable seamless knowledge sharing that drives improvements in the standard of care for people living with immuno-dermatological conditions.

The IFPA Conference 2024 promises to offer an enriching experience with clinically relevant discussions and a patient-centric approach. It also provides an inspiring forum to ignite meaningful conversations on raising the standards of care in psoriasis and psoriatic arthritis. If you are attending, connect with #Team��ֳ� on-site!

��ֳ� has a proven heritage in immunology. We harness evidence-based science to deliver solutions and services that address persistent unmet needs across the healthcare ecosystem. By leveraging data, technology, and innovative scientific research, we aim to improve the lives of people living with these diseases.

about ucb

psoriasis IFPA2024 psoriatic arthritis

236 Likes

Transforming rheumatology

Vanco Vlastimil (��ֳ� S.A.) — Fri, 12 May 2023 07:00:00 +0000

Transforming rheumatology

Athanasia Gkiouleka, Rheumatology Mission

Vanco Vlastimi… Fri 12/05/2023 - 09:00

At ��ֳ�, we embrace the possibility to transform the lives of people living with psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), systemic lupus erythematosus (SLE) and osteoporosis.

Despite the progress made in recent years, there remains a significant unmet need for people living with rheumatic diseases. We are hopeful, however, that the solid foundation established in partnership with the scientific community provides the opportunity to elevate care for people living with rheumatic diseases, allowing them to live as free as possible from the challenges and uncertainty caused by their disease.

Building on more than 30 years of research, we are now exploring approaches to move from symptomatic treatment to disease modification and cure. Our evolving rheumatology portfolio gives us the potential to deliver and expand value for numerous patient populations, including those living with axSpA, PsA and osteoporosis.

Through our unique mix of expertise, innovation and ambition, we aim to pioneer and accelerate scientific advancements which make a meaningful difference to people living with rheumatic diseases. Have a look at the infographic below to learn how ��ֳ� is aiming to transform rheumatology.

Inspired by patients, driven by science, we are ��ֳ�.

To learn more about ��ֳ�’s commitment to people living with rheumatic diseases, visit www.ucb.com/disease-areas

about ucb

rheumatology psoriatic arthritis axial spondyloarthritis Systemic lupus erythematosus osteoporosis

440 Likes

Exploring the future of dermatology at AAD 2023

Vanco Vlastimil (��ֳ� S.A.) — Fri, 17 Mar 2023 11:22:35 +0000

Exploring the future of dermatology at AAD 2023

Eimear O'Brien, Global Communications & Company Reputation

Vanco Vlastimi… Fri 17/03/2023 - 12:22

The American Academy of Dermatology (AAD) Annual Meeting takes place this week in New Orleans, Louisiana, U.S., 17-21 March. We spoke with Braulio Gomez, U.S. Medical, ��ֳ� and Owen Davies, Global Medical, ��ֳ� to find out more.

What can you tell us about AAD 2023?
Braulio Gomez: AAD 2023 is among the largest and most significant yearly meetings in the field of dermatology. Each year, this meeting brings together the community for a comprehensive learning experience, offering scientific sessions that comprise symposia, forums and interactive workshops. Hosted in New Orleans this year, it is anticipated that the meeting will attract thousands of medical professionals from all over the world. The event provides an opportunity for distinguished experts, clinicians, and scientists to share their expertise, best practices, and insights in the field of dermatology. As a long-standing participant of AAD, ��ֳ� is committed to advancing research in and to providing solutions that meet the needs of patients across a range of dermatological conditions. We look forward to connecting with the community this week to share and discuss the latest research, collaborate with peers, and explore the future of dermatology.

Can you share more about ��ֳ�’s commitment in the area of dermatology?
Owen Davies: ��ֳ� is committed to improving the lives of individuals affected by immune-mediated inflammatory diseases, and we are passionate about creating a world where these diseases no longer impose a burden on patients. We believe that collaborating closely with the community is crucial to achieving this goal, as it leads to a deeper understanding of patients’ needs, advances in clinical knowledge and scientific understanding. Our Patient Value Strategy places the patient and their experiences at the forefront of everything we do. Through our dermatology partnerships we are able to build strong connections with both the patient and scientific communities. This close collaboration enables us to gain a deep scientific understanding of dermatological conditions and helps us to enhance standards of care and demonstrate our dedication to improving patient outcomes.

Can you tell us about ��ֳ�’s scientific presence at AAD 2023?
Owen Davies: This year, we are excited to share our latest research in moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe hidradenitis suppurativa. We are thrilled to be presenting eight abstracts, which have been accepted as seven posters and one oral platform presentation. These abstracts represent the culmination of our commitment to advancing dermatology research and improving the standard of care for individuals affected by these conditions.

What can healthcare professionals expect to experience at the medical section of ��ֳ�’s booth?
Braulio Gomez: At the medical section of the booth, delegates can look forward to an interactive and immersive experience with the opportunity to learn more about hidradenitis suppurativa, psoriatic arthritis and psoriasis. If you are a healthcare professional attending AAD 2023, we look forward to welcoming you to our booth, where you will have the opportunity to meet members of our ��ֳ� team, discuss the latest research, and explore further innovative approaches to help address patients’ needs.

What are your hopes for the future of dermatology?
Braulio Gomez and Owen Davies: Scientific understanding of many inflammatory dermatological diseases is advancing at an incredible rate – but there’s still much to be done to help people living with these debilitating diseases live to the fullest. At ��ֳ�, we share a vision of a future where innovative science and technology drive progress in disease management. With increased understanding of conditions such as hidradenitis suppurativa, psoriasis, and psoriatic arthritis, we believe that pioneering new approaches to disease management will emerge, providing hope for patients and healthcare providers alike.
Collaboration is also key to growing our collective, scientific understanding of dermatological conditions and we always look for ways to work closely with the most passionate partners as we strive to improve every stage of the patient journey. We look forward to continuing our close collaborations with all stakeholders and we believe that our shared commitment to advancing dermatology research will result in a brighter future for patients and healthcare providers.

Stay up to date with ��ֳ� news from the 2023 AAD Annual Meeting by following us on our social media channels, including Twitter and LinkedIn.

about ucb

AAD 2023 dermatology research Hidradenitis Suppurativa psoriasis psoriatic arthritis

482 Likes

Uniting with the Community for World Psoriasis Day 2022

Vanco Vlastimil (��ֳ� S.A.) — Thu, 27 Oct 2022 08:40:23 +0000

Uniting with the Community for World Psoriasis Day 2022

Rajesh Gupta, Patient Value Immunology & US Solutions

Vanco Vlastimi… Thu 27/10/2022 - 10:40

Each year on October 29, the global community unites for World Psoriasis Day to raise awareness, spread information and increase knowledge about psoriatic disease. ��ֳ� is proud to support this day, led by the International Federation of Psoriatic Disease Associations (IFPA). Each year, World Psoriasis Day, takes a different theme to highlight the many aspects of this disease, with this year’s focus being on mental health.

Psoriasis and psoriatic arthritis are multifaceted conditions affecting multiple parts of the body, like the skin, joints, or both. People living with these conditions can come at an increased risk of developing co-morbidities such as obesity, diabetes, and cardiovascular disease. Living with these physical symptoms and risks can be debilitating and can cause a significant social and emotional burden, impacting mental health and quality of life. Approximately 125 million people worldwide are living with psoriasis. An estimated 30% of people with psoriasis go on to develop psoriatic arthritis.

Mental health is recognized as an integral part of health and well-being. Raising awareness and educating on the wider impact of psoriasis and psoriatic arthritis can increase understanding and help ease the stigma associated with these conditions. At ��ֳ�, we have a long-term commitment to help improve the lives of people living with psoriasis and psoriatic arthritis. By uniting with the community to address unmet needs, support clinical research and build strong, collaborative advocacy partnerships, we aim to make a meaningful difference.

We look forward to a future where the people living with these conditions can unload the burden caused by the challenges and uncertainties of disease.

solutions

World Psoriasis Day IFPA psoriasis psoriatic arthritis

Comment:

Posted by Leah Howard, JD, 28 October 2022

As CEO of the National Psoriasis Foundation, I want to thank you for highlighting the significant burden of living with psoriatic disease. We share your optimism for the future and invite anyone living with or caring for someone living impacted by psoriasis or psoriatic arthritis to take advantage of NPF's free resources and support at psoriasis.org. Together, we will achieve our vision of a life free of psoriatic disease and their burdens.

356 Likes

Looking forward to an exceptional EADV 2022 experience

Vanco Vlastimil (��ֳ� S.A.) — Wed, 07 Sep 2022 08:56:22 +0000

Looking forward to an exceptional EADV 2022 experience

Owen Davies, Global Medical Affairs

Vanco Vlastimi… Wed 07/09/2022 - 10:56

The 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy, will welcome leading clinical experts, healthcare professionals and advocates in the fields of dermatology and venereology in person, and virtually, between September 7–10. At this year’s congress, we are thrilled to be showcasing a wide breadth of data from across our expanding dermatology portfolio, with 20 ��ֳ� posters being presented.

Featuring over 600 speakers across more than 170 sessions, EADV 2022 aims to shape the future of dermatology and venereology by facilitating scientific discussion, networking and collaboration. We are proud to be contributing significantly to the high-quality scientific research and debate, demonstrating our commitment to improving standards of care in dermatology.

Among the 20 ��ֳ� poster presentations, we will be sharing new three-year data from the BE BRIGHT open-label extension study in adults with moderate to severe plaque psoriasis. We are also supporting four scientific sessions where world-leading experts in dermatology will be communicating the newest approaches and advances in care.

Dermatological conditions such as psoriasis and psoriatic arthritis affect millions of people around the world and can have a considerable impact on quality of life. While there have been great strides in this field so far, the work does not stop here. Together with the community, we continue to strive for more, by continuing with research, sharing new data and hosting sessions so we can collectively make a difference for those living with chronic inflammatory skin diseases.

EADV 2022 promises to be another ground-breaking meeting with an outstanding programme of educational and learning opportunities for dermatologists and venereologists worldwide. If you are a healthcare professional attending EADV 2022, we hope to welcome you to our exhibition booth and educational sessions, both virtually and in person.

We are looking forward to an exceptional EADV experience. You can stay informed about ��ֳ� news at EADV 2022 through our social media channels (Twitter, LinkedIn).

about ucb

EADV European Academy of Dermatology and Venereology psoriasis psoriatic arthritis chronic inflammatory diseases

447 Likes

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

Vandenbruaene Nathalie — Wed, 01 Jun 2022 08:56:30 +0000

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

John Ioannou, Medical Affairs, Rheumatology

Vandenbruaene … Wed 01/06/2022 - 10:56

As an organisation, we always feel a great sense of pride when ��ֳ� takes part in the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, and this year feels extra special. EULAR is celebrating an impressive milestone – its 75th anniversary – and the congress is being held as a hybrid congress for the very first time.

Thousands of delegates from across the world will be coming together both virtually and on-site in Copenhagen, Denmark. The opportunity to connect virtually for the last two years has been invaluable, however, being able to meet with some of our friends and colleagues in person for scientific exchange is something I am sure we are all looking forward to.

At this year’s congress, ��ֳ� will be sharing a wealth of new and important clinical data. In particular, we are proud to be sharing the first presentations of our pivotal Phase 3 data from our extensive research programmes in psoriatic arthritis and axial spondyloarthritis. The depth of our research programmes is testimony to our continuing commitment to delivering real value for people living with these conditions.

In addition, our three sponsored scientific symposia will bring the rheumatology community together to discuss and debate ‘Raising the Target for Patients Living with Psoriatic Arthritis’, ‘Raising the Target for Patients Living with Axial Spondyloarthritis’ and ‘Evolving Concepts in axSpA-2022 Update’. To enhance scientific exchange, we are also pleased to support a ‘Consult the Expert’ session focused on enthesitis management. We look forward to continuing discussions around the latest advancements in the rheumatology field at our exhibition booth, where members of our ��ֳ� team will be ready and pleased to welcome all those in attendance.

We are honoured to be partnering with our esteemed colleagues and peers to drive the future of rheumatology at this year’s congress. We look forward to being a part of EULAR 2022!

You can stay up to date on the latest ��ֳ� news at EULAR 2022 through our social media channels (Twitter, LinkedIn).

about ucb

EULAR Rheumatology psoriatic arthritis axial spondyloarthritis

473 Likes

��ֳ� Recognizes World Arthritis Day 2020

eCMSadmin — Mon, 12 Oct 2020 08:30:00 +0000

��ֳ� Recognizes World Arthritis Day 2020

Andrea Christopher, Global Communications & Company Reputation

eCMSadmin Mon 12/10/2020 - 10:30

Today we are shining a light on World Arthritis Day in efforts to raise awareness of patients living with rheumatic and musculoskeletal diseases (RMDs), including rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), as part of ��ֳ�’s ongoing commitment to the rheumatology community.

��ֳ� has been proudly leading the way in connecting innovative science to unmet needs in specific patient populations, such as women of childbearing age and patients with axSpA and PsA. We are committed to providing a transformative experience for these patients.

As we lean into ��ֳ�’s Accelerate & Expand phase, it is our ambition to lead the way in providing holistic solutions that address patient needs at all key milestones in their healthcare journey.

Our innovative research in axSpA and PsA has laid a solid foundation to help us achieve our future vision for meeting the needs of these patients. There is great opportunity to innovate and improve care for patients with axSpA, starting with earlier and more accurate diagnoses.

Additionally, with the launch of the Advantage Hers campaign last month, we are continuing to highlight the unmet needs and unique challenges of women living with rheumatic diseases and other chronic inflammatory conditions.

Furthermore, we are empowering and equipping these patients to have informed conversations with their specialist about creating a management plan that is best tailored to their individual needs.

World Arthritis Day, led by the European League Against Rheumatism (EULAR), aims to help people living with RMDs avoid long-term complications by improving education of the condition, promoting early diagnosis and encouraging access to care.

EULAR’s campaign theme ‘Don’t Delay, Connect Today,’ calls on the public, physicians, policymakers and health professionals to connect and diagnose RMDs earlier and provide timely access to evidence-based treatment.

RMDs impact hundreds of millions of people worldwide and predominantly affect a person’s joints, muscles and connective tissues, causing pain and loss of physical function.

Today, and every day, ��ֳ� remains dedicated to providing innovative solutions to people living with these diseases and to raising public awareness of the importance of early diagnosis and available treatment options.

solutions

World Arthritis Day 2020 rheumatic diseases psoriatic arthritis musculoskeletal diseases axial spondyloarthritis Advantage Hers

743 Likes

Inflammatory diseases: Big news on small molecules

eCMSadmin — Tue, 04 Feb 2020 14:00:00 +0000

Inflammatory diseases: Big news on small molecules

James O’Connell, Research & Early Development

eCMSadmin Tue 04/02/2020 - 15:00

��ֳ� has been a leader in biological therapies for inflammatory conditions, including rheumatoid arthritis. Now, our scientists have unveiled a discovery that could build on our small molecule heritage in medicinal chemistry – and open the door to a new wave of therapies for people with serious conditions.

TNF is a protein known to play a key role in inflammation. The development of biological therapies that block or inhibit TNF paved the way for a range of therapies that improved the lives of people with rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis.

Take rheumatoid arthritis, for example. ��ֳ� has played an important role in bringing monoclonal antibodies – which are a leading form of anti-TNF medication – to many patients around the world. By inhibiting TNF activity, inflammation can be significantly reduced. This eases patients’ symptoms and can spare them irreparable damage to their joints.

This was a major breakthrough for medical science in the late 20th century. For decades, researchers searched for ‘small molecules’ that could disrupt TNF activity and give patients the relief they needed. Despite the best efforts of the scientific community, it appeared that small molecules (pills) could not deliver the effect required. Monoclonal antibodies (injectables), which are much larger molecules, changed everything.

However, the idea of small molecules that could affect TNF activity never went away. These elusive compounds were considered to be ‘high-hanging fruit’ in the scientific community, but there is good reason to pursue this Holy Grail.

Small molecules offer several advantages over larger biological therapies:, they can be taken orally which is convenient for patients, and they have shorter half-lives – which is beneficial to patients that need to stop taking their medication quickly.

They also have potential to cross the blood-brain barriers which could allow doctors to treat inflammatory diseases of the central nervous system. For example, inflammation may play a role in neurodegenerative conditions.

��ֳ� was founded more than 90 years ago and made its mark in medical science by focusing on small molecules. Biological therapies are now a key component of our effort to improve the lives of patients, but our small molecule expertise remains. This experience and our active interest in autoimmune diseases inspired our scientists to explore new ways in which small molecules could influence TNF.

A new paper, published in Nature Communications by 16 current and former ��ֳ� scientists, unveils an important step forward in this quest. They describe the first ever genuine small molecule antagonist of TNF. This could be the beginning of another new chapter for people living with inflammatory diseases for which there are currently no oral anti-TNF medicines available.

For the first time we have been able to show that TNF-receptor interactions can be tackled with small molecules, not by taking on the interface where the partners interact, (which would be impossible), but by locking one of the partners in a signaling-incompetent state. We discovered that TNF naturally moves and flips between different conformations all the time; some of these are biologically active, and some aren’t. We took advantage of this understanding to design small chemical compounds which bind to these moving targets and restrict the movement to ensure clinically-desired outcomes. It’s like using a grain of sand (small molecule) in the hinge of a door, rather than your arm (biologic), to stop it swinging. This new thinking makes these targets druggable using medicinal chemistry that has been applied to targets such as enzymes for a hundred years.

We are delighted that a broad team effort has delivered this entirely new advance in medical science and hope to see this science translated into life-changing therapies for people in need.

innovation

Rheumatoid arthritis TNF small molecules psoriatic arthritis psoriasis Nature Communication inflammation axial spondyloarthritis

577 Likes

psoriatic arthritis

Redefining immunology care: our pledge to patients and the healthcare community

Leave a Comment

��ֳ� Joins the Dermatology Community for #IFPAConference2024

Here are some highlights of ��ֳ�’s presence at the IFPA Conference 2024:

Leave a Comment

Transforming rheumatology

Leave a Comment

Exploring the future of dermatology at AAD 2023

Leave a Comment

Uniting with the Community for World Psoriasis Day 2022

Leave a Comment

Looking forward to an exceptional EADV 2022 experience

Leave a Comment

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

Leave a Comment

��ֳ� Recognizes World Arthritis Day 2020

Leave a Comment

Inflammatory diseases: Big news on small molecules

Leave a Comment

psoriatic arthritis

Redefining immunology care: our pledge to patients and the healthcare community

Leave a Comment

������ֳ� Joins the Dermatology Community for #IFPAConference2024

Here are some highlights of ������ֳ�’s presence at the IFPA Conference 2024:

Leave a Comment

Transforming rheumatology

Leave a Comment

Exploring the future of dermatology at AAD 2023

Leave a Comment

Uniting with the Community for World Psoriasis Day 2022

Leave a Comment

Looking forward to an exceptional EADV 2022 experience

Leave a Comment

EULAR 2022: ������ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

Leave a Comment

������ֳ� Recognizes World Arthritis Day 2020

Leave a Comment

Inflammatory diseases: Big news on small molecules

Leave a Comment

��ֳ� Joins the Dermatology Community for #IFPAConference2024

Here are some highlights of ��ֳ�’s presence at the IFPA Conference 2024:

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

��ֳ� Recognizes World Arthritis Day 2020